Nivolunix 100 mg (Nivolumab) Injection

Nivolunix 100 contains Nivolumab, an immune checkpoint inhibitor that helps strengthen the body's natural immune response against cancer cells. It is used in the management of selected advanced or metastatic malignancies, either as monotherapy or in combination with other anticancer agents, based on clinical guidelines and physician recommendations.

Therapeutic Effects:

• Enhances T-cell mediated immune activity against tumor cells.
• Helps slow disease progression in eligible patients.
• Supports long-term disease control in certain cancers.
• Improves the immune system's ability to recognize and target malignant cells.

Common Clinical Uses:

• Advanced or metastatic melanoma
• Non-small cell lung cancer (NSCLC)
• Renal cell carcinoma (kidney cancer)
• Classical Hodgkin lymphoma
• Head and neck squamous cell carcinoma
• Urothelial carcinoma
• MSI-H/dMMR colorectal cancer
• Hepatocellular carcinoma
• Esophageal cancer and other approved indications

Active Ingredient:

• Nivolumab INN

Strength:

• 100 mg / 10 mL

Pharmaceutical Form:

• Concentrate for Solution for Intravenous Infusion

Composition:

Each 10 mL vial contains:

• Nivolumab INN ............... 100 mg

The formulation is designed for intravenous administration under the supervision of qualified healthcare professionals experienced in oncology treatment.

Recommended Dosage:

The dosage regimen should be individualized according to the patient's condition, body weight, treatment protocol, and current clinical guidelines. Therapy must be initiated and monitored by an experienced oncology specialist.

Route of Administration:

• Intravenous (IV) infusion only.

Administration Guidance:

• Administer as a diluted intravenous infusion over the recommended infusion period.
• Do not administer as an intravenous push or bolus injection.
• Follow institutional preparation and handling procedures for cytotoxic and specialty medicines.
• Treatment duration depends on therapeutic response and tolerability.

Missed Dose:

If a scheduled infusion appointment is missed, patients should contact their healthcare provider promptly to arrange an alternative treatment schedule. The dose should not be doubled to compensate for a missed administration.

Important Instructions:

• Use only under medical supervision.
• Monitor patients regularly for immune-mediated adverse reactions.
• Dose modifications or treatment interruption may be required based on safety assessments and clinical response.